Omalizumab (Xolair) is a monoclonal antibody that is recommended as add-on treatment in patients with severepersistent uncontrolled allergic asthma. It is currently prescribed in severe asthmatics sensitized to perennialallergens, which are thought to be responsible for the persistent status of inflamed airways. This is the case fordust mite, which has been associated with severe asthma.However, other allergens can cause perennial allergy–like conditions and therefore—albeit with reduced prevalence—severe asthma.
Different skin prick test sensitization patterns do not influence the response to omalizumab in severe asthma
Cavaliere, C;
2017-01-01
Abstract
Omalizumab (Xolair) is a monoclonal antibody that is recommended as add-on treatment in patients with severepersistent uncontrolled allergic asthma. It is currently prescribed in severe asthmatics sensitized to perennialallergens, which are thought to be responsible for the persistent status of inflamed airways. This is the case fordust mite, which has been associated with severe asthma.However, other allergens can cause perennial allergy–like conditions and therefore—albeit with reduced prevalence—severe asthma.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
